Author Topic: Connection between DMTs and cancer-risk in MS patients?  (Read 133 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8223
  • MS diagnosed 1980
  • Location: Pacific Northwest
More on this topic--from PubMed, October 25, 2016:

Quote
J Neurol Sci. 2016 Nov 15;370:13-17.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D1, Kavak KS2, Teter B3, Vaughn CB3, Cookfair D4, Hahn T5, Weinstock-Guttman B6; New York State Multiple Sclerosis Consortium.

Author information


1Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, Buffalo, NY, USA.
2Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo, NY, USA.
3Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo, NY, USA; Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA.
4Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA.
5Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
6Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, Buffalo, NY, USA; New York State MS Consortium, University at Buffalo, Buffalo, NY, USA; Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA. Electronic address: bweinstock-guttman@kaleidahealth.org.

BACKGROUND:

Although dysimmunity is considered an important link between multiple sclerosis (MS), family history and cancer risk, their relationship to the use of disease modifying therapies (DMT) is not fully understood.

OBJECTIVE:

To assess the observed versus expected number of cancers in MS patients, and family history of cancer, among DMT users and DMT-na´ve patients.

METHODS:

Cancer, DMT use, and family history of cancer were assessed using the New York State Multiple Sclerosis Consortium (NYSMSC) registry. Self-reported cancers in MS patients were tested for associations with DMT use, family history of cancer and other factors. Expected number of cancer cases was estimated using age- and gender-specific prevalence and incidence rates from the general population.

RESULTS:

The prevalence of cancer in males and females in the NYSMSC cohort was lower than expected (p<0.001). Patients with cancer were older at MS diagnosis and more likely to be female (p<0.001). MS patients with a personal history of cancer were more likely to report DMT use (p<0.001) and family history of cancer (p<0.001). Multivariable analysis did not support a higher risk of cancer after DMT initiation.

CONCLUSIONS:

We report a lower than expected number of cancer cases in MS patients compared to the general population. MS patients with a personal history of cancer were more likely to report DMT use suggesting that DMTs may abrogate the lower incidence of cancer in MS.

The abstract can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
52 Views
Last post October 25, 2016, 08:56:06 am
by agate
0 Replies
44 Views
Last post May 16, 2017, 12:21:07 pm
by agate
0 Replies
101 Views
Last post August 24, 2017, 03:56:38 pm
by agate
0 Replies
48 Views
Last post December 26, 2017, 09:11:30 pm
by agate
1 Replies
37 Views
Last post October 12, 2018, 08:34:59 am
by agate